Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86. Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Unique COVID-19 possibility
Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86. Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely.